{"id":"W4395109358","doi":"10.1093/ehjcvp/pvae025","title":"Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; Sanofi (Canada); University of Alberta; St. Michael's Hospital","funders":"Duke Clinical Research Institute; American Regent; St. Jude Medical; Esperion Therapeutics; Idorsia Pharmaceuticals; Servier; MyoKardia; Novo Nordisk; Daiichi-Sankyo; Regado Biosciences; Belvoir Media Group; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Boston VA Research Institute; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; Amgen; Sanofi; American Heart Association","keywords":"Alirocumab; PCSK9; Medicine; Internal medicine; LDL receptor; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002410986,0.0007205987,0.004044986,0.0003715963,0.0001839042,0.00007192237,0.0005415866,0.0002426495,0.0001024401],"category_scores_gemma":[0.00008997823,0.0004657948,0.01397525,0.001035505,0.0001660195,0.000162628,0.0001886668,0.001948106,0.0000921587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003199625,"about_ca_system_score_gemma":0.0008438577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001073714,"about_ca_topic_score_gemma":9.464284e-7,"domain_scores_codex":[0.9901062,0.004004704,0.002304168,0.0007017525,0.002442836,0.0004403155],"domain_scores_gemma":[0.9963755,0.0001061804,0.000860649,0.001884998,0.0004088742,0.0003637933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009831423,0.0001263899,0.00001236686,0.006417313,0.01847098,0.0003525989,0.000522346,0.00002942972,0.0003163012,0.000008212195,0.002385844,0.9712599],"study_design_scores_gemma":[0.002014682,0.0001824209,0.0003633648,0.02079352,0.01119722,0.001224574,0.00003762673,0.000004503357,0.0004441755,0.00001566123,0.963338,0.0003842368],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005110615,0.989333,0.0001030455,0.000066466,0.002688709,0.002057967,0.0001412683,0.00005638572,0.0004425589],"genre_scores_gemma":[0.001745683,0.9929359,0.0003966196,0.0003636975,0.004016649,0.00002045296,0.00006169754,0.0003570681,0.0001022153],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9708757,"threshold_uncertainty_score":0.9997794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05757911266128796,"score_gpt":0.325943084739561,"score_spread":0.2683639720782731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}